PMID: 6159648Sep 1, 1980Paper

Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension

Proceedings of the National Academy of Sciences of the United States of America
J BurtonE Haber

Abstract

The angiotensin substrate analog Pro-His-Pro-Phe-His-Phe-Phe-Val-Tyr-Lys has no significant effect on blood pressure in sodium-replete monkeys (Macaca fascicularis) but blocks the pressor response to infused human renin. Pressor responses to angiotensin I and angiotensin II are not attenuated. In five studies in sodium-depleted monkeys, an infusion of 2 mg of the peptide per kg of body weight resulted in a reduction of mean arterial pressure (MAP) from 105 +/- 4 to 79 +/- 3 mm Hg, which is not significantly different from the response to 1 mg of the angiotensin I-converting enzyme inhibitor teprotide per kg. In uninephrectomized monkeys, inflation of a suprarenal aortic cuff caused an increase in MAP from 107 +/- 3 to 131 +/- 3 mm Hg. Infusion of 0.6 mg of the renin-inhibitory peptide per kg was followed by a return of blood pressure to 107 +/- 4 mm Hg--a depressor response similar to that observed with teprotide. This specific in vivo inhibitor of renin can now be applied to a wide variety of physiologic studies.

References

Jan 1, 1979·Annual Review of Pharmacology and Toxicology·A Scriabine
May 1, 1972·Proceedings of the Society for Experimental Biology and Medicine·G R KeimJ W Poutsiaka
Nov 1, 1974·Journal of Medicinal Chemistry·M C KhoslaF M Bumpus

❮ Previous
Next ❯

Citations

Sep 1, 1994·Journal of Clinical Pharmacology·W H FrishmanC Dike
Apr 1, 1990·Medicinal Research Reviews·W J Greenlee
Nov 1, 1993·Medicinal Research Reviews·S S Abdel-Meguid
Oct 1, 1995·Cardiovascular Drugs and Therapy·H D Kleinert
Sep 15, 1988·Klinische Wochenschrift·K G Hofbauer, J M Wood
Nov 15, 1988·European Journal of Pharmacology·A T ChiuP B Timmermans
Apr 1, 1988·Regulatory Peptides·D G ChangarisR S Levy
Oct 1, 1994·Biophysical Chemistry·G J AndersonA F Drake
Nov 1, 1993·Trends in Cardiovascular Medicine·E Haber
May 10, 2005·The Journal of Steroid Biochemistry and Molecular Biology·Guilin QiaoYan Chun Li
Dec 20, 1984·The New England Journal of Medicine·E Haber
Jun 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J B MichelJ Ménard
Aug 19, 2007·Cardiology in Review·Reza SepehrdadDomenic A Sica
Nov 16, 1987·European Journal of Biochemistry·J CooperM Szelke
Oct 1, 1984·The Journal of Clinical Investigation·J A Oliver, R R Sciacca
Jun 23, 2011·Heart Failure Reviews·Nicolas F SchrotenRudolf A de Boer
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·D T PalsG F Skala
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·K TakaoriJ Burton
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·S PapaioannouM Clare
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·E Haber
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·B LeckieM Tree
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·K G HofbauerJ M Wood
Jan 1, 1984·Clinical and Experimental Hypertension. Part A, Theory and Practice·E E SlaterL H Hartley
Sep 1, 1988·The American Journal of the Medical Sciences·R T Talwalkar, T A Kotchen
Apr 1, 1985·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·E Haber
Jul 1, 2004·The Journal of Steroid Biochemistry and Molecular Biology·Yan Chun LiJuan Kong
Jan 1, 1991·The American Journal of Cardiology·G W NeubergM Packer
Jan 1, 1989·Fundamental & Clinical Pharmacology·P Corvol, J Menard
May 1, 1996·American Heart Journal·C Lin, W H Frishman
Apr 6, 1993·Biochemistry·A J Beveridge, G C Heywood
Jan 1, 1987·Journal of Enzyme Inhibition·J M WoodK G Hofbauer
Jul 1, 1990·Hypertension·P CorvolJ Ménard
Nov 1, 1983·Hypertension·E HaberA C Barger
Apr 15, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Alice Stanton
Dec 1, 1986·Hypertension·D T PalsG A Johnson
Aug 17, 2005·Hypertension·Darren J KellyRichard E Gilbert
Mar 1, 1991·Hypertension·K HigashimoriT Inagami
Jun 1, 1988·Hypertension·K HiwadaY Iijima
Sep 1, 1985·Hypertension·J M WoodK G Hofbauer
Jun 1, 1989·Hypertension·P F MentoB M Wilkes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.